Aclarion Announces New Real-World Publication: Nociscan® Validated by Strong Agreement with Discography in Diagnosing Painful Lumbar Discs

An independent study at London Spine Clinic found Aclarion’s noninvasive Nociscan agreed with discography in identifying painful discs in up to 87% of cases, across 55 discs in 20 patients. At the study site, a three-disc Nociscan exam cost approximately £2,040 versus roughly £2,775 for discography, and patients avoided the two days of work missed due to pain flare-ups often associated with discography. The authors noted the small sample and said larger multicenter studies are being organized; they said the method may eventually replace discography in appropriately selected patients.

Analysis

This is a credibility signal, not yet an earnings signal for Aclarion (ACON). The investment mechanism is whether independent evidence converts into repeat physician use, reimbursed testing, and recurring SaaS revenue; the release provides no utilization, reimbursement, pricing mix, or revenue-conversion data. The 20-patient study is too small to establish clinical utility, and agreement with discography does not prove diagnostic accuracy when the comparator itself is debated. Disc-level observations may also be correlated within patients. The company’s 97% surgical-success claim is not independently established by this study and should not be capitalized as an outcome guarantee.

Near term, a press-release-driven move could outrun evidence of commercial traction. Over 1–3 months, watch for actual center additions, paid test volumes, payer coverage, and multi-center protocol/results; these matter more than another endorsement. Over 6–18 months, broader validation and reimbursement could support adoption, while slow evidence generation or limited MRI/MRS access would constrain scaling. Potential workflow winners are spine clinics and patients if testing avoids invasive procedures; any displacement of discography-related revenue is unquantified. The key contrarian point: 87% agreement sounds compelling, but does not establish that Nociscan changes treatment decisions or improves outcomes. Thesis weakens if subsequent studies show materially poorer performance, or if adoption and reimbursement fail to translate into reported revenue.

Key Decisions for Investors

• Do not chase the announcement alone. Treat ACON as a catalyst watch until the company reports paid test volumes, repeat utilization, reimbursement status, and revenue contribution; verify cash runway and dilution exposure in filings before sizing any position.
• For an event-driven approach, wait for the initial news reaction to settle, then consider only a small, defined-risk long if price action holds and follow-up evidence includes multi-center data or verifiable commercial adoption. No defensible price target is available from the supplied information.
• Track the next clinical and commercial milestones: study size and patient-level diagnostic performance, whether results alter surgical decisions, new center activations, payer coverage, and reported Nociscan revenue. Failure to produce these indicators over the next few quarters would invalidate the adoption thesis.
• Avoid treating the claimed 97% surgical success rate or single-site cost comparison as underwritten economics; seek independent outcome data and evidence that the test’s cost and workflow advantages persist across sites and payers.